Erratum

This article refers to:

Lenalidomide in multiple myeloma: current role and future directions

In the article “Lenalidomide in multiple myeloma: current role and future directions”, by Zeldis et al. (Expert Opin. Pharmacother. (2010) 11:829-842), an error has been identified. Some of the reference citation numbers in column 2 of Tables 4 and 5 were incorrect. The corrected tables are shown below.

Table 4. Lenalidomide-containing regimens under evaluation in relapsed/refractory myeloma.

Regimen: lenalidomide plus	Ref.
Bortezomib, dexamethasone	[51,53]
Bortezomib, dexamethasone, doxorubicin	[50,52]
Doxorubicin, dexamethasone	[55]
Pegylated doxorubicin, vincristine, dexamethasone	[54]
Cyclophosphamide, dexamethasone	[56]
Cyclophosphamide, prednisone	[57]
Vorinostat, dexamethasone	[58]
Panobinostat, dexamethasone	[59]
Bevacizumab, dexamethasone	[60]
Perifosine, dexamethasone	[61]
Elotuzumab, dexamethasone	[62]

Table 5. Lenalidomide-containing regimens under evaluation in newly diagnosed myeloma.

Regimen: lenalidomide plus	Ref.
Bortezomib, dexamethasone	[66,67]
Bortezomib, dexamethasone, cyclophosphamide	[64]
Bortezomib, dexamethasone, doxorubicin	[63]
Clarithromycin, dexamethasone (BiRD)	[69]
Cyclophosphamide, dexamethasone	[65]
Melphalan	[68]
Melphalan, prednisone	[70,71]

Informa Healthcare and the authors of this article would like to apologize for any confusion caused.